8-K: Cardiff Oncology's Onvansertib Shows Strong Efficacy in mCRC

Cardiff Oncology reports positive Phase 2 data for Onvansertib in first-line RAS-mutant mCRC, showing significant improvement in objective response rates and progression-free survival, leading to plans for a registrational trial.

Summary

• Onvansertib, an oral, highly selective PLK1 inhibitor, is being developed for first-line RAS-mutant metastatic colorectal cancer (mCRC), a population with high unmet need.
• The CRDF-004 Phase 2 trial in first-line RAS-mutated mCRC demonstrated a confirmed Objective Response Rate (ORR) of 72.2% in the 30 mg onvansertib + FOLFIRI/bevacizumab arm, representing a 30% improvement over the FOLFIRI standard of care (SoC).
• Median Progression-Free Survival (PFS) has not yet been reached in either the 20 mg or 30 mg onvansertib + FOLFIRI/bevacizumab arms, compared to 10.97 months for the FOLFIRI/bevacizumab SoC arm.
• Favorable dose-dependent trends were observed in PFS hazard ratios, with 0.38 for the 30 mg onvansertib + FOLFIRI/bevacizumab arm versus FOLFIRI/bevacizumab SoC (p=0.048 vs combined SoC).
• The 30 mg onvansertib dose in combination with FOLFIRI/bevacizumab has been selected for the registrational program due to its efficacy and no significant added toxicity.
• Onvansertib + FOLFOX/bevacizumab arms did not demonstrate benefit in RAS-mutated mCRC.
• An investigator-initiated Phase 1 trial of onvansertib monotherapy in Chronic Myelomonocytic Leukemia (CMML) showed encouraging early activity, with preliminary efficacy in approximately 40% of patients, including complete responses and blast reduction.
• Cardiff Oncology had $58.3 million in cash, cash equivalents, and short-term investments as of December 31, 2025, projected to fund operations into the first quarter of 2027.
• Pfizer is a partner in the CRDF-004 trial through its Breakthrough Growth Initiative, providing clinical execution and a $15 million investment, while Cardiff Oncology retains full economic ownership.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this filing as highly positive due to the exceptionally strong efficacy data from the CRDF-004 trial, particularly the high ORR and unreached PFS, which significantly exceed current standard of care and historical benchmarks in a high-unmet-need indication. The clear path to a registrational trial and Pfizer's continued partnership further bolster confidence.

Positives

• Confirmed Objective Response Rate (ORR) of 72.2% in the 30 mg onvansertib + FOLFIRI/bevacizumab arm, a 30% improvement over FOLFIRI standard of care.
• Median Progression-Free Survival (PFS) has not yet been reached in the onvansertib + FOLFIRI/bevacizumab arms, indicating prolonged disease control.
• Strong PFS hazard ratio of 0.38 for the 30 mg onvansertib dose (p=0.048 vs combined SoC), suggesting a significant reduction in the risk of progression or death.
• No significant added toxicity observed with onvansertib in combination with FOLFIRI/bevacizumab.
• Two patients in the 30 mg onvansertib + FOLFIRI/bevacizumab arm achieved complete response (CR) and were referred for curative surgery.
• Encouraging early activity of onvansertib as monotherapy in the orphan disease CMML, with preliminary efficacy in ~40% of patients.
• Pfizer's involvement as a CRO partner and investor validates the potential of onvansertib and provides financial and operational support.
• Sufficient cash runway into Q1 2027, providing financial stability for upcoming clinical milestones.

Negatives

• Onvansertib + FOLFOX/bevacizumab arms did not demonstrate benefit in RAS-mutated mCRC, limiting the combination's applicability to FOLFIRI/bevacizumab.
• The p-value for ORR (0.051 vs SoC) is just above the conventional significance threshold of 0.05, though still indicative of a strong trend.
• The CRDF-004 trial is a Phase 2 dose-finding study, and larger Phase 3 registrational trials are still needed to confirm these results.

Risks

• Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
• Clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of the product candidate.
• Results of preclinical studies or clinical trials for the product candidate could be unfavorable or delayed.
• The company has a need for additional financing.
• Risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks on information technology infrastructure, which could seriously harm financial condition and increase costs and expenses.
• Uncertainties of government or third-party payer reimbursement.
• Dependence on key personnel.
• Limited experience in marketing and sales.
• Substantial competition in the oncology market.
• Uncertainties of patent protection and litigation.
• Dependence upon third parties for various aspects of development and commercialization.
• Risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.
• No guarantees that the product candidate will be utilized or prove to be commercially successful.

Future Outlook

Cardiff Oncology plans to hold an FDA meeting within the first half of 2026 to review its registrational program for onvansertib in first-line RAS-mutant mCRC, with potential for accelerated approval based on ORR and Duration of Response. The company expects to initiate its Phase 3 registrational trial (CRDF-005) in the second half of 2026, comparing 30 mg onvansertib + FOLFIRI/bevacizumab to standard of care. Additionally, the company will continue to expand onvansertib's potential across other PLK1-driven cancers through ongoing investigator-sponsored studies.

Management Comments

• Mani Mohindru is serving as the Interim Chief Executive Officer of Cardiff Oncology, Inc.

Industry Context

StockSavvy.ai notes that the first-line treatment landscape for RAS-mutated metastatic colorectal cancer (mCRC) has seen limited innovation for two decades, with chemotherapy plus bevacizumab remaining the standard of care. Onvansertib's strong efficacy signals, particularly the 72.2% ORR and unreached median PFS in the 30 mg FOLFIRI/bevacizumab arm, position it as a potential breakthrough in this underserved population. The drug's mechanism, targeting PLK1, offers a novel approach compared to existing therapies, which primarily focus on chemotherapy or anti-angiogenic agents. The market for RAS-mutated mCRC is substantial, representing approximately 50% of first-line mCRC patients, indicating significant commercial opportunity if approved.

Comparison to Industry Standards

• Onvansertib (CRDF-004) demonstrated a confirmed ORR of 72.2% in the 30 mg FOLFIRI/bevacizumab arm, significantly higher than historical controls for first-line mCRC. For example, Bevacizumab (IFL/bev vs IFL) showed an ORR of 45% vs 35%, and FOLFOXIRI/bev (TRIBE trial) showed 65% vs 54%.
• The median PFS for onvansertib + FOLFIRI/bevacizumab arms has not yet been reached, which compares favorably to the 10.97 months for FOLFIRI/bevacizumab SoC. Historical trials like Bevacizumab reported PFS of 10.6 vs 6.2 months, and FOLFOXIRI/bev reported 12.3 vs 9.7 months.
• The PFS Hazard Ratio (HR) of 0.38 for 30 mg onvansertib + FOLFIRI/bevacizumab (vs SoC) is notably better than the HRs reported for Bevacizumab (0.54) and FOLFOXIRI/bev (0.77) in their respective trials, suggesting a more pronounced reduction in disease progression risk.

Stakeholder Impact

• Shareholders: Potential for significant value creation if onvansertib successfully progresses through clinical development and gains regulatory approval, given the large market opportunity and strong efficacy data.
• Patients: Offers a promising new treatment option for first-line RAS-mutant mCRC, a population with limited therapeutic innovation and high unmet need, potentially leading to improved outcomes.
• Employees: Positive clinical results and a clear development path can boost morale and attract talent.
• Competitors: Onvansertib's strong data could pose a competitive threat to existing and pipeline therapies for mCRC, especially in the RAS-mutated segment.

Next Steps

• Report detailed CRDF-004 Phase 2 data in first-line RAS-mutated mCRC in 1H 2026.
• Announce registrational strategy and Phase 3 trial design following consultation with FDA in 1H 2026.
• Initiate registrational program / Phase 3 trial (CRDF-005) in first-line RAS-mutated mCRC in 2H 2026.
• Continue expansion across additional PLK1-driven cancers through ongoing investigator-sponsored studies (e.g., CMML, mPDAC, SCLC, TNBC).

Key Dates

Recommendation

The filing presents exceptionally strong clinical data for Onvansertib in first-line RAS-mutant mCRC, an area with significant unmet medical need and a large market. The 72.2% ORR and unreached median PFS, coupled with a highly favorable hazard ratio, significantly outperform current standard of care and historical benchmarks. The clear regulatory path towards a registrational trial, potential for accelerated approval, and the continued partnership with Pfizer de-risk the development process. While future trials are required, the current data suggest a high probability of success and substantial commercial potential, making Cardiff Oncology a strong buy for investors seeking exposure to innovative oncology assets.

Keywords

Onvansertib, RAS-mutant mCRC, Colorectal Cancer, PLK1 inhibitor, Oncology, Clinical Trial, FDA approval, Metastatic Colorectal Cancer, CMML, Cardiff Oncology